Open AccessCertolizumab pegol: new opportunities for treatment of moderate to severe plaque psoriasis
Author(s) -
А. А. Кубанов,
А. А. Кубанов,
А. Л. Бакулев,
А. Л. Бакулев,
М. И. Глузмин,
М. И. Глузмин,
М. М. Кохан,
М. М. Кохан,
Л. С. Круглова,
Л. С. Круглова,
Н. С. Руднева,
Н. С. Руднева,
O. Yu Olisova,
О Ю Олисова,
E. V. Sokolovsky,
Е В Соколовский,
М. М. Хобейш,
М. М. Хобейш
Publication year - 2019
Publication title -
vestnik dermatologii i venerologii
Language(s) - English
Resource type - Journals
eISSN - 2313-6294
pISSN - 0042-4609
DOI - 10.25208/0042-4609-2019-95-5-50-57
Subject(s) - certolizumab pegol , psoriatic arthritis , medicine , psoriasis , arthritis , infliximab , tumor necrosis factor alpha , tnf inhibitor , clinical trial , pharmacology , immunology
Tumor necrosis factor alpha (TNF-α) is one of the key inflammatory cytokines in the pathogenesis of psoriasis and psoriatic arthritis, and its inhibition with genetically engineered biological drugs ensures control of the main symptoms of these diseases. Certolizumab pegol is a PEGylated (linked to polyethylene glycol) Fab’ fragment of a monoclonal antibody that inhibits human TNF-α. It is approved for treatment of moderate to severe plaque psoriasis and psoriatic arthritis. This review summarizes the results of randomized clinical trials of efficacy and safety of certolizumab pegol in plaque psoriasis (CIMPASI 1, CIMPASI 2, and CIMPACT) and psoriatic arthritis (Rapid-PsA). The represented data demonstrate high efficacy of certolizumab pegol is bio-naïve patients and in patients previously exposed to other TNF inhibitors or IL17 inhibitors. The absence of the Fc-fragment in certolizumab pegol ensures minimal to no placental transfer of the drug and enables its usage during the entire pregnancy. Conflict of interest: the authors state that there is no potential conflict of interest requiring disclosure in this article.